Spero Therapeutics SPRO
NASDAQ SPRO
$1.16 -0.01 (-0.85%)
As of: Sep 10, 2026 · 11:31 AM EDT

Spero Therapeutics (SPRO) Net Margin (QoQ) (2016 - 2026)

Analysis

Spero Therapeutics (SPRO) Net Margin (QoQ) (2016 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.86 Bn 192.87 Bn 7.24 Bn
2 Gilead Sciences 179.52 Bn 176.34 Bn 6.22 Bn
3 Vertex Pharmaceuticals 131.47 Bn 123.62 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 61.16 Bn 55.98 Bn 1.37 Bn
6 Moderna 53.15 Bn 48.02 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.20 Bn 29.89 Bn 992.69 Mn
8 Biogen 31.65 Bn 30.37 Bn 1.96 Bn
9 Roivant Sciences 29.30 Bn 29.30 Bn 1.16 Mn
10 Spero Therapeutics 67.24 Mn 16.47 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -286,394.00
Dec 31, 2025 20,811.00
Sep 30, 2025 -12,364.00
Jun 30, 2025 22,406.00
Mar 31, 2025 -10,108.00
Dec 31, 2024 -338.00
Sep 30, 2024 4,357.00
Jun 30, 2024 -3,862.00
Mar 31, 2024 -20,619.00
Dec 31, 2023 8,221.00
Sep 30, 2023 42,586.00
Jun 30, 2023 20,264.00
Mar 31, 2023 -69,751.00
Dec 31, 2022 63,843.00
Sep 30, 2022 72,101.00
Jun 30, 2022 15,349.00
Mar 31, 2022 -45,701.00
Dec 31, 2021 -26,731.00
Sep 30, 2021 -37,359.00
Jun 30, 2021 -9,413.00